Easing adoption, accelerating commoditization and lowering costs. That’s how it works everywhere else. Why not in healthcare? In my interview of experts from Innovative Health, the largest U.S. medical device reprocessor specializing in cardiology, they all reinforced the same point: hospital decision-makers still must turn the tables on the manufacturer.
Adele is bringing the firm she co-founded, 1315 Capital, L.P., into the newest round for the cosmetics company that Mary spun off from SkinMedica. Colorescience raised $15-million in Series C financing in a round led by 1315.
Another noteworthy feature of emerging managers is that many of them have created new or different models for their firms and for making VC investments. “We leverage a unique, team-based operating partner model of CEO and longtime executive partners who collaborate with us,” said Adele Oliva, Founding Partner of Philadelphia-based healthcare expansion and growth equity …
A new study published in Journal of the International Society of Sports Nutrition shows the combination of amylopectin and chromium in Nutrition 21’s patented ingredient Velositol doubles the muscle protein synthesis rate compared to what was seen when using whey protein alone.
Past and present commissioners of the U.S. Food and Drug Administration, both with ties to Duke University, are among the speakers headlining the Council for Entrepreneurial Development’s 26th annual Life Science Conference next month in Raleigh. Confirmed speakers at the conference include Adele Oliva, Ibraheem Badejo, and James C. Greenwood.
The Philadelphia Business Journal honored Adele Oliva as part of the Power 76, a guide to the region’s most influential people. They narrowed in on those wielding the most influence, either through their position, their connections or their money. These are the people with the most impact in shaping the future of Greater Philadelphia.
1315 Capital today announced the final closing of its $200 million inaugural fund. The fund is led by seasoned healthcare investors and 1315 Capital’s Co-Founders, Adele Oliva and Michael Koby, and includes a select group of high quality investors, including endowments, foundations, state and corporate pension funds, and family offices.
Onkos Surgical and Vivex Biomedical, Inc. have come together to provide a portfolio of tissue products to support the needs of musculoskeletal oncologists and their patients. This commitment strengthens Onkos Surgical’s ability to enhance outcomes, decrease complications and improve recovery following musculoskeletal tumor and limb salvage surgery.
Nutrition 21, LLC, a leading developer and marketer of efficacious, patented nutritional products whose health benefits are substantiated with clinical research, announced today that Sara O’Brien has joined as General Counsel of JDS Therapeutics, and its wholly owned subsidiary Nutrition 21.
Onkos Surgical, a dedicated surgical oncology company founded to bring innovation, advocacy and passion to the surgical oncology marketplace, supported a difficult chondrosarcoma case with the use of a 3D printed medical model.